Curis, Inc. (CRIS) Coverage Initiated by Analysts at Guggenheim
Investment analysts at Guggenheim started coverage on shares of Curis, Inc. (NASDAQ:CRIS) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.
CRIS has been the topic of several other reports. Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. ValuEngine cut Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, BidaskClub upgraded Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $6.00.
Shares of Curis (NASDAQ:CRIS) remained flat at $1.57 on Monday. 729,679 shares of the stock traded hands. The firm’s 50-day moving average is $1.73 and its 200 day moving average is $1.92. Curis has a one year low of $1.47 and a one year high of $3.72. The firm’s market capitalization is $225.89 million.
Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). The firm had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) earnings per share. Equities research analysts anticipate that Curis will post ($0.40) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of CRIS. Prudential Financial Inc. bought a new position in shares of Curis during the 1st quarter worth approximately $105,000. American International Group Inc. raised its position in shares of Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 4,560 shares during the period. FMR LLC raised its position in shares of Curis by 2.7% during the first quarter. FMR LLC now owns 15,131,961 shares of the biotechnology company’s stock worth $42,067,000 after purchasing an additional 393,582 shares during the period. Vanguard Group Inc. raised its position in shares of Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after purchasing an additional 304,268 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Curis by 8.3% during the first quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock worth $2,553,000 after purchasing an additional 70,139 shares during the period. Hedge funds and other institutional investors own 44.72% of the company’s stock.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.